期刊文献+

恶性疟原虫对青蒿素产生抗性的研究进展 被引量:31

Research Progress on Artemisinin Resistance in Plasmodium falciparum
下载PDF
导出
摘要 青蒿素及其衍生物是我国发明的强效抗疟药,WHO已推荐以青蒿素为基础的联合用药(ACTs)为治疗恶性疟的一线药物。青蒿素及其衍生物的应用已使全球疟疾流行得到了有效控制,疟疾发病率和死亡率逐年下降。但近年来,在东南亚多个地区陆续报道恶性疟原虫(Plasmodium falciparum)对青蒿素类药物产生抗性,并有进一步扩散的趋势,这已严重威胁到全球疟疾防治和消除疟疾计划的实施。本文综述近年来恶性疟原虫对青蒿素产生抗性研究领域的相关研究进展,包括青蒿素抗药性的检测方法、抗性相关的分子标记、抗性虫株的起源及传播流行等。 Artemisinin (ART) is a novel and effective antimalarial drug discovered in China. As recommended by the World Health Organization, the ART-based combination therapies (ACTs) have become the first- line drugs for the treatment of falciparum malaria. ART and its derivatives have contributed greatly to the effective control of malaria globally, leading to yearly decrease of malaria morbidity and mortality. However, there have recently been several reports on the resistance of Plasmodium falciparum to ART in Southeast Asia. This is deemed a serious threat to the global malaria control programs. In this paper, we reviewed recent research progress on ART resistance to P. falciparum, including new tools for resistance measurement, resistance-associated molecular markers, and the origin and spread of the ART-resistant parasite strains.
出处 《中国寄生虫学与寄生虫病杂志》 CAS CSCD 北大核心 2015年第6期418-424,共7页 Chinese Journal of Parasitology and Parasitic Diseases
关键词 青蒿素 恶性疟原虫 抗药性 起源 Artemisinin Plasmodium falciparum Drug resistance Origin
  • 相关文献

参考文献67

  • 1Marsh K. Malaria disaster in Africa [J]. Lancet, 1998, 352 (9132): 924. 被引量:1
  • 2Harinasuta T, Suntharasamai P, Viravan C. Chloroquine-resistant falciparum malaria in Thailand[J]. Lancet, 1965, 286(7414): 657-660. 被引量:1
  • 3Muregi FW, Kirira PG, Ishih A. Novel rational drug design strategies with potential to revolutionize malaria chemotherapy[J]. Curr Med Chem, 2011, 18(1): 113-143. 被引量:1
  • 4Sat JM, Twu O, Hayton K, et O1. Geographic patterns of Plasmodium folciparum drug resistance distinguished by differ- ential responses to amodiaquine and chloroquine [J ]. Proc Natl Acad Sci USA, 2009, 106(45): 18883-18889. 被引量:1
  • 5Hawkins VN, Auliff A, Prajapati SK, et d. Multiple origins of resistance-conferring mutations in Plasmodium vivax dihy- drofolate reductase[J]. Malar J, 2008, 7(1): 72. 被引量:1
  • 6Baird, J K. Chloroquine Resistance in Plasmodium vivax[J]. Antimicrob Agents Chemother, 2004, 48(11): 4075-4083. 被引量:1
  • 7WHO. Guidelines for the treatment of malaria [R]. Geneva: WHO, 2006. 被引量:1
  • 8Barnes KI, Durrheim DN, Little F, et al. Effect of Artemether- lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa[J]. PLoS Med, 2005, 2(11): e330. 被引量:1
  • 9Carrara VI, Sirilak S, Thonglairuam J, et ol. Deployment of early diagnosis and mefloquine-artesunate treatment of falci- parum malaria in Thailand: the Tak Malaria Initiative [J]. PLoS Med, 2006, 3(6): e183. 被引量:1
  • 10Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin- resistant malaria in western Cambodia [J]. N Engl J Med, 2008, 359(24): 2619-2620. 被引量:1

共引文献4

同被引文献208

引证文献31

二级引证文献123

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部